Mark R. Middleton - Publications, H-index & Citations

Mark R. Middleton

university of oxford

79H指数

752论文数

3.0W被引数

收录论文 188

发表时间

Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY Study 多癌种早期检测测试在癌症症状调查中的诊断意义：SYMPLIFY研究的一项探索性回顾性分析

The Lancet Regional Health - Europe

IF0

2026-05-28

OAAI

Ashley Jackson; Pradeep S. Virdee; Sharon Tonner; Jason L. Oke; Rafael Perera; Kaveh Riahi; Sara Hiom; Harpal Kumar; F.D. Richard Hobbs; Mark R. Middleton; Brian D. Nicholson

Correction: Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England 更正：多癌筛查测试（MCTs）在初级保健中的偏好：英格兰全科医生和普通公众的离散选择实验

British Journal of Cancer

IF6.8

2025-12-01

OAAI

John Buckell; Nomalanga Madyiwa; Gail Hayward; Mark R. Middleton; FD Richard Hobbs; James Buchanan; Apostolos Tsiachristas; Brian D. Nicholson

Establishing the China–UK Cancer Prevention and Control Alliance 建立中英癌症预防与控制联盟

lancet oncology

IF0

2025-09-01

PREAI

Jun Ma; David Kerr; Yuankai Shi; Charles Swanton; Tony Mok; Rebecca Fitzgerald; Rui-Hua Xu; Richard Cowan; Rong Lin; Mark Lawler; Gao-Jun Teng; Tim Eisen; Molly Li; Maria Kyrgiou; Fanny Wai San Ko; Mark Middleton; Binghe Xu; Eric Aboyage; Dan Xiao; Yi-Long Wu; Arnie Puroshotham; Li Yang; Daiming Fan

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade CMV血清状态与抗PD-1检查点阻断后生存改善和毒性发作延迟相关

NATURE MEDICINE

IF50

2025-04-23

OAAI

Milotay, Gusztav; Little, Martin; Watson, Robert A.; Muldoon, Dylan; Mackay, Sophie; Kurioka, Ayako; Tong, Orion; Taylor, Chelsea A.; Nassiri, Isar; Webb, Louisa M.; Akin-Adigun, Oluwafemi; Bremke, Julia; Ye, Weiyu; Sun, Bo; Sharma, Piyush Kumar; Cooper, Ros; Danielli, Sara; Santo, Flavia Matos; Verge de los Aires, Alba; Niu, Guangyi; Cohen, Lea; Ng, Esther; Gilchrist, James J.; Chong, Amanda Y.; Mentzer, Alex; Woodcock, Victoria; Coupe, Nicholas; Payne, Miranda J.; Youdell, Michael; Middleton, Mark R.; Klenerman, Paul; Fairfax, Benjamin P.

The role of circulating tumor DNA in melanomas of the uveal tract

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-12-04

OAAI

Zameer, Mohammed Zeeshan; Jou, Eric; Middleton, Mark

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial

ESMO OPEN

IF8.3

2024-11-01

PREAI

Scanlon, E.; Lavery, A.; Albraikat, M.; Stevenson, L.; Kennedy, C.; Byrne, R.; Walker, A.; Mullan-Young, B.; McManus, D. T.; Virdee, P. S.; Elhussein, L.; Turbitt, J.; Collinson, D.; Miedzybrodzka, Z.; Van Schaeybroeck, S.; McQuaid, S.; James, J. A.; Craig, S. G.; Blayney, J. K.; Petty, R. D.; Harkin, D. P.; Kennedy, R. D.; Eatock, M. M.; Middleton, M. R.; Thomas, A.; Turkington, R. C.

The molecular basis of the lymphocyte stability index (LSI): A pan-cancer peripheral biomarker for survival post immune checkpoint blockade (ICB)淋巴细胞稳定性指数（LSI）的分子基础：一种全癌种外周生物标志物，用于免疫检查点阻断（ICB）后的生存预测

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Watson, R.; Tong, O.; Little, M.; Muldoon, D.; Mackay, S.; Oluwafemi, A-A.; Sun, S.; Milotay, G.; Taylor, C.; Vallance, G.; Shine, B.; Middleton, M. R.; Coupe, N. A.; Payne, M.; Fairfax, B. P.

Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)I期安全性及有效性研究：brenetafusp（一种PRAME x CD3 ImmTAC T细胞结合剂）在铂耐药卵巢癌（PROC）中的应用

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Friedman, C.; Williams, A. De Burgh; Lopez, J. S.; Ouali, K.; Middleton, M. R.; Thistlethwaite, F.; Hamid, O.; Izar, B.; Garcia, V. Moreno; Johnson, M. L.; Davar, D.; Martin-Liberal, J.; Roxburgh, P.; Moore, K. N.; Olson, D.; Rottey, S.; Kirk, P. B.; Yuan, Y.; Marshall, S.; Yeku, O.

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study 在一项开放标签1b/2期研究中，Binimetinib与nivolumab或nivolumab和ipilimumab联合治疗先前治疗过的微卫星稳定的转移性结直肠癌患者的RAS突变

BMC CANCER

IF3.4

2024-04-11

OAAI

Elez, Elena; Cubillo, Antonio; Alfonso, Pilar Garcia; Middleton, Mark R.; Chau, Ian; Alkuzweny, Baha; Alcasid, Ann; Zhang, Xiaosong; Van Cutsem, Eric

High tumor monocyte content predicts long-term survival for patients with operable oesophageal cancer treated with neoadjuvant immunochemotherapy in the LUD2015-005 trial

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Fuchs, Hannah S.; James, Sabrina A.; Carroll, Thomas M.; Xie, Phil F.; Chadwick, Joseph A.; Parkes, Duncan; Lord, Simon R.; Griffiths, Lucinda; Underwood, Tim; Karydis, Ioannis; Petty, Russell T.; Schuster-Bockler, Benjamin; Owen, Richard P.; Middleton, Mark R.; Lu, Xin

A cell-free DNA methylation biomarker outperforms irRECIST in predicting treatment outcome

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Xie, Phil; Innoue, Masato; Siejka-Zielinska, Paulina; Amess, Robert; Chang, Jaeho; Wilding, Sam; Griffiths, Gareth; Middleton, Mark R.; Owen, Richard P.; Song, Chunxiao; Lu, Xin; Schuster-Boeckler, Benjamin

Enhanced CD8+T-cell infiltration, PD-L1 expression, and T-cell repertoire expansion in patients with metastatic uveal melanoma responding to treatment with RP2 alone or in combination with nivolumab

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Bommareddy, Praveen K.; Kalbasi, Alireza; Harrington, Kevin J.; Olsson-Brown, Anna; Chan, Tze Y.; Nenclares, Pablo; Leslie, Isla; Middleton, Mark R.; Cohan, David M.; Xynos, Konstantinos; Coffin, Robert; Sacco, Joseph J.

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial 尼洛替尼治疗试剂盒驱动的晚期黑色素瘤: II期单臂NICAM试验的结果

CELL REPORTS MEDICINE

IF10.6

2024-03-01

OAAI

Larkin, James; Marais, Richard; Porta, Nuria; de Castro, David Gonzalez; Parsons, Lisa; Messiou, Christina; Stamp, Gordon; Thompson, Lisa; Edmonds, Kim; Sarker, Sarah; Banerji, Jane; Lorigan, Paul; Evans, Thomas R. Jeffry; Corrie, Pippa; Marshall, Ernest; Middleton, Mark R.; Nathan, Paul; Nicholson, Steve; Ottensmeier, Christian; Plummer, Ruth; Bliss, Judith; Valpione, Sara; Turajlic, Samra

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)在BRAFV600突变晚期黑色素瘤患者中间歇与连续给药dabrafenib联合曲美替尼的随机2期研究 (中期)

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-01-01

OAAI

Dayimu, Alimu; Gupta, Avinash; Matin, Rubeta N.; Nobes, Jenny; Board, Ruth; Payne, Miranda; Rao, Ankit; Fusi, Alberto; Danson, Sarah; Eccles, Bryony; Carser, Judith; Brown, Ciara O'Hanlon; Steven, Neil; Bhattacharyya, Madhumita; Brown, Ewan; Gonzalez, Michael; Highley, Martin; Pickering, Lisa; Kumar, Satish; Waterston, Ashita; Burghel, George; Demain, Leigh; Baker, Eleanor; Wulff, Jerome; Qian, Wendi; Twelves, Sophie; Middleton, Mark; Corrie, Pippa

Long term outcomes of immune checkpoint inhibition in oesophageal cancer

BRITISH JOURNAL OF SURGERY

IF8.7

2023-11-18

OAAI

Owen, Richard; Fuchs, Hannah; James, Sabrina; Lord, Simon; Underwood, Tim; Karydis, Ioannis; Petty, Russell; Middleton, Mark; Lu, Xin

The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB)

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

PREAI

Watson, R. A.; Tong, O.; Taylor, C.; Vallance, G.; Santo, F. Matos; Little, M.; Sun, B.; Shine, B.; Middleton, M. R.; Coupe, N. A.; Payne, M.; Fairfax, B. P.

A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

PREAI

Gupta, A.; Matin, R. N.; Dayimu, A.; Nobes, J.; Board, R. E.; Payne, M.; Rao, A. R.; Fusi, A.; Danson, S.; Eccles, B. K.; Carser, J.; Brown, C. O'Hanlon; Steven, N.; Burghel, G. J.; Demain, L.; Baker, E. C.; Wulff, J.; Twelves, S.; Middleton, M. R.; Corrie, P. G.

BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Shoushtari, A. N.; Middleton, M. R.; Hamid, O.; Meier, F.; Bauer, T.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P.; Mauch, C.; Orloff, M.; Edukulla, R.; Goodall, H.; Hassel, J. C.; Evans, T. R. J.

Identification of a subset of metastatic melanoma patients demonstrating germline determined insensitivity to immunotherapy

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Fairfax, B. P.; Taylor, C.; Watson, R. A.; Ye, W.; Tong, O.; Santo, F. Matos; Coupe, N. A.; Middleton, M. R.; Payne, M.

A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

PREAI

Blackhall, F.; Moliner, L.; Samson, A.; Franks, K.; Karydis, I.; Joseph-Pietras, D.; Frank, O.; Lavender, H.; Jannoo, M.; Marshall, M.; Motteram, P.; Van den Eynde, B. J.; Leung, C.; Hill, A.; Middleton, M. R.; Coupe, N. A.; Steele, N.; Spicer, J.; Shaw, P. H.; Symeonides, S. N.

研究方向